The information in Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing
[DOI] [PMC free article] [PubMed] [Google Scholar] 146.Perissinotti PP, Martinez-Hernandez E, Piedras-Renteria ES
[DOI] [PubMed] [Google Scholar] 24.Hay D.L., Chen S., Lutz T.A., Parkes D.G., Roth J.D
Retatrutide is currently the most powerful weight loss peptide in clinical development, producing 24.2% average weight loss over 48 weeks in Phase 2 trials
Only way is to have a blood test .Mine has always been fine